PTGX as reported
Protagonist Therapeutics, Inc. reported $282M of revenue over the trailing twelve months, +35% on the year before. 9 reported series are charted on this page, each one as filed.
$282M
Revenue, trailing twelve months · to Q2 2026 · +35% against the twelve months before
- Net Income
- $83M
Net Income · +59% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $131M
Free Cash Flow · +252% year on year · trailing twelve months to Q2 2026
- Op Margin
- −399%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $282M | +35% | Q2 2026 |
| Net Income | $83M | +59% | Q2 2026 |
| EPS | $1.02 | +40% | Q2 2026 |
| Op Margin | −399% | n/a | Q2 2026 |
| Net Margin | −337% | n/a | Q2 2026 |
| ROE | −5.4% | n/a | Q2 2026 |
| ROA | −5.0% | n/a | Q2 2026 |
| Free Cash Flow | $131M | +252% | Q2 2026 |
| P/E | 149 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Protagonist Therapeutics, Inc. (PTGX) - Revenue & ProfitRevenue & ProfitProtagonist Therapeutics, Inc. (PTGX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com